Associations of serum bile acids and amino acids with low skeletal muscle mass among Chinese population: a cross-sectional study

中国人群血清胆汁酸和氨基酸与低骨骼肌质量的相关性:一项横断面研究

阅读:1

Abstract

BACKGROUND: Sarcopenia, characterized by progressive muscle loss, burdens aging populations. While bile acids (BAs) in skeletal muscle mass (SMM) are poorly understood, the role of amino acids (AAs) remains debated. This study investigated the associations between serum BAs, AAs, and low SMM in Chinese adults. METHODS: Among 2170 initially enrolled participants, 702 were finally analyzed. Participants were classified into low and normal SMM groups. Serum BAs and AAs were quantified by targeted LC-MS/MS. Nonlinear relationships were assessed using restricted cubic spline analysis. Mediation analysis was used to assess the mediating effects of metabolic factors. RESULTS: The prevalence of low SMM was 14.5% (females: 21.1% vs. males: 10.2%). Multivariable logistic regression identified that increased glycocholic acid (GCA, OR = 0.561, p = 0.030), glycolithocholic acid (GLCA, OR = 0.255, p < 0.001) and deoxycholic acid (DCA, OR = 0.444, p = 0.003) were independently associated with lower risk of low SMM in the fully adjusted model. Valine (OR = 0.646, p = 0.010) and leucine (OR = 0.680, p = 0.024) showed consistent protective effects against low SMM at physiological concentrations. Mediation analysis showed BMI mediated protective effects of GCA, valine and leucine (all p < 0.01), while creatinine/cystatin C ratio mediated leucine's effect (p = 0.030). Notably, GLCA exhibited direct protection independent of metabolic mediators (both p < 0.01). CONCLUSIONS: This study identified specific BAs and AAs significantly correlated with preserved SMM, suggesting that modulating BA metabolism (particularly elevating GLCA) and maintaining optimal BCAA levels may be effective strategies for low SMM. GLCA's direct protective effect supports exploring dietary or microbiota-targeted interventions. Individual metabolic profiles, such as BMI, should be incorporated into personalized sarcopenia management.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。